Shant Torkom Yeretzian

Shant Torkom Yeretzian

Auto-generated profile, based on publicly available information

Shant Torkom Yeretzian

Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2023 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
SYShant Torkom Yeretzian
Shant Torkom Yeretzian
YSYeva Sahakyan
Yeva Sahakyan
NKNicole Kozloff
Nicole Kozloff
LALusine Abrahamyan
Lusine Abrahamyan

1 January 2024 in Journal of Clinical Oncology
Verified
Journal Article
Open access
YSYeva Sahakyan
Yeva Sahakyan
QLQixuan Li
Qixuan Li
SAShabbir Alibhai
Shabbir Alibhai
Martine PutsMartine Puts
Martine Puts
SYShant T. Yeretzian
Shant T. Yeretzian
LALusine Abrahamyan
Lusine Abrahamyan
PURPOSE: Geriatric assessment (GA) is a guideline-recommended approach to optimize cancer management in older adults. We conducted a cost-utility analysis alongside the 5C randomized controlled trial to compare GA and management (GAM) plus usual care (UC) against UC alone in older adults with cancer. METHODS: The economic evaluation, conducted from societal and health care payer perspectives, used a 12-month time horizon. The Canadian 5C study randomly assigned patients to receive GAM or UC. Quality-adjusted life-years (QALYs) were measured using the EuroQol five dimension-5L questionnaire and health care utilization using cost diaries and chart reviews. We evaluated the incremental net monetary benefit (INMB) for the full sample and preselected subgroups. RESULTS: A total of 350 patients were included, of whom 173 received GAM and 177 UC. At 12 months, the average QALYs per patient were 0.728 and 0.751 for GAM and UC, respectively (ΔQALY, −0.023 [95% CI, −0.076 to 0.028]). Considering a societal perspective, the total average costs (in 2021 Canadian dollars) per patient were $46,739 and $45,177 for GAM and UC, respectively (ΔCost, $1,563 [95% CI, −$6,583 to $10,403]). At a cost-effectiveness threshold of $50,000/QALY, GAM was not cost-effective compared with UC (INMB, −$2,713 [95% CI, −$11,767 to $5,801]). The INMB was positive ($2,984 [95% CI, −$7,050 to $14,179]; probability of being cost-effective, 72%) for patients treated with curative intent, but remained negative for patients treated with palliative intent (INMB, −$9,909 [95% CI, −$24,436 to $4,153]). Findings were similar considering a health care payer perspective. CONCLUSION: To our knowledge, this is the first cost-utility analysis of GAM in cancer. GAM was cost-effective for patients with cancer treated with curative but not with palliative intent. The study provides further considerations for future adoption of GAM in practice.

10 January 2026 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SASelai Akseer
Selai Akseer
SYShant Torkom Yeretzian
Shant Torkom Yeretzian
LALusine Abrahamyan
Lusine Abrahamyan
Martine PutsMartine Puts
Martine Puts
MMMostafa Mohamed
Mostafa Mohamed
YSYeva Sahakyan
Yeva Sahakyan
PURPOSE: Geriatric assessment and management (GAM) is a guideline-recommended strategy for optimizing cancer management among older adults. A recent cost-utility analysis of the Canadian 5C randomized controlled trial (RCT) found GAM to be cost effective for selected groups. This study aimed to assess the cost-utility of GAM plus usual care (UC) versus UC alone in older adults with cancer using a decision model and best available evidence from four international RCTs—GAIN, GAP70, INTEGERATE, and 5C. METHODS: For the model, we used pooled data from four RCTs and peer-reviewed literature. Deterministic and probabilistic analyses were performed from the Canadian health care payer perspective, applying a 6-month time horizon. Sensitivity analyses included per-trial scenario analyses, 1-year time horizon, and US health care payer perspective. We reported costs per quality-adjusted life year (QALY) and incremental net monetary benefit (INMB). RESULTS: The base-case analysis indicated that GAM had an INMB of $599 in Canadian dollars (CAD; 95% credibility interval, –$3,428 to $4,742) with 60.9% probability of being cost effective at a threshold of $50,000 (CAD) per QALY. Trial-specific results varied, with the GAP70 and INTEGERATE trials yielding positive INMB ($2,231 [CAD] and $2,104 [CAD], respectively), suggesting cost-effectiveness, whereas 5C and GAIN resulted in negative INMB (–$489 [CAD] and –$234 [CAD], respectively). Chemotherapy and hospitalization costs were the main driver of costs in both strategies. CONCLUSION: GAM is overall cost effective, with results varying across trial scenarios due to differences in chemotherapy dose intensity, hospitalization rates, and associated costs. Future research should prioritize identifying optimal core GAM components, delivery mode, and patient selection criteria to enhance its effectiveness and cost-effectiveness.

28 November 2025 in BMJ Open
Verified
Journal Article
Open access
SYShant Torkom Yeretzian
Shant Torkom Yeretzian
CSCarly Sillcox
Carly Sillcox
HLHannah Loshak
Hannah Loshak
LRLauren Ramsay
Lauren Ramsay
YSYeva Sahakyan
Yeva Sahakyan
BSBeate H Sander
Beate H Sander
Introduction: Economic evaluations are essential for informing healthcare resource allocation. When conducted from a societal perspective, they may include productivity costs such as paid and unpaid productivity losses for patients and their caregivers. Although several methods exist to measure and value productivity costs, there is limited methodological consensus on which methods should be used. This scoping review aims to synthesise existing methods for measuring and valuing patient and caregiver productivity costs. Methods and analysis: This review will follow the Arksey and O’Malley framework, enhanced by subsequent methodological guidance from Levac and the Joanna Briggs Institute. The six stages include identifying the research question; identifying relevant studies; selecting studies; charting the data; collating, summarising and reporting the results; and consultation. We will search MEDLINE, Embase and EconLit from 1996 to July 2025. Eligible sources will include peer-reviewed literature that reports methods for the measurement or valuation of productivity costs related to paid or unpaid work among patients or caregivers. Screening and data extraction will be conducted independently by two reviewers. Extracted data will include types of productivity costs, instruments used, valuation approaches, as well as recommendations on preferred measurement and valuation methods. Results will be synthesised thematically and reported using the Preferred Reporting Items for Systematic Review and Meta-Analysis for Scoping Reviews checklist. Ethics and dissemination: Ethics approval is not required as this review will rely exclusively on publicly available literature and does not involve human participants or the use of primary data. The findings will first be shared with Canada’s Drug Agency as a report and then disseminated through peer-reviewed publication and academic presentations to inform future research and practice. Registration: This protocol has been registered with the Open Science Framework ( https://doi.org/10.17605/OSF.IO/FK9D4 ).

26 June 2026 in International Journal of Technology Assessment in Health Care
Verified
Journal Article
Open access
PDF file
SYShant Torkom Yeretzian
Shant Torkom Yeretzian
CSCarly Sillcox
Carly Sillcox
HLHannah Loshak
Hannah Loshak
LRLauren Ramsay
Lauren Ramsay
ABAlex Gregory Rodriguez Barizonte
Alex Gregory Rodriguez Barizonte
BSBeate H Sander
Beate H Sander

5 November 2023 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
SAS. Alibhai
S. Alibhai
MAM.R. Anwar
M.R. Anwar
Martine PutsMartine Puts
Martine Puts
SYS. Yeretzian
S. Yeretzian
AAA. Ayala
A. Ayala
LAL. Abrahamyan
L. Abrahamyan